I n attempting to elucidate the hitherto poorly understood action of the prostanoid-EP 1 receptor, researchers in the US have uncovered a new type of receptor interaction and demonstrated its action on murine airway smooth muscle contraction. Prostaglandin E 2 (PGE 2 ) produces its diverse biological effects by acting on four endogenous receptor subtypes (EP 1 -EP 4 ). The authors set out to define the action of the EP 1 receptor. In a series of experiments they first showed that activation of EP 1 receptors by PGE 2 failed to cause contraction of mouse tracheal ring, as might have been expected, but did cause a marked reduction in b 2 adrenergic receptor (b 2 AR) mediated relaxation. This was shown to be mediated at the level of the receptor itself. This suggested an interplay between the EP 1 receptor and the b 2 AR, with activation of the former resulting in decreased function of the latter. They went on to demonstrate coupling of the two receptors into a heterodimer. Activation of the EP 1 receptor within the heterodimer causes a conformational change in the b 2 AR, uncoupling it from its G protein with resultant desensitisation to b 2 AR agonists.
This study demonstrates a novel modulatory function of the EP 1 receptor in regulating the action of the b 2 AR. This may contribute to the reduced response to b 2 AR agonists in severe asthma, when there may be increased concentrations of endogenous PGE 2. , took adults with a pneumonia severity index score of (110 and randomly assigned those who substantially improved after 72 hours of intravenous amoxicillin to either 750 mg oral amoxicillin (n = 63) or placebo (n = 56) three times daily for 5 days thereafter.
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Clinical, bacteriological and radiological outcomes were assessed. The clinical success rate at day 10 (per protocol analysis) was 93% in both groups (50/54 in the 3 day treatment group and 56/60 in the 8 day treatment group: difference 0.1% (95% CI 29 to 10)). At day 28 clinical success rates were 90% (47/52) in the 3 day treatment group and 88% (49/56) in the 8 day treatment group (difference 2% (95% CI 29 to 15)). There was therefore little difference between the two groups.
This study suggests that a short course of antibiotic therapy is not inferior to a longer course in patients with mild to moderate-severe uncomplicated community acquired pneumonia who show clinical improvement after 3 days of intravenous antibiotics.
